
GENMAB AS DK 1
Share · DK0010272202 · 565131 (XCSE)
200,40 EUR
10.06.2025 17:44
Current Prices from GENMAB AS DK 1
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() Frankfurt |
GE9.F
|
EUR
|
10.06.2025 17:44
|
200,40 EUR
| 194,75 EUR
+2,90 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | 4,10 % | 13,22 % | -1,81 % | -4,30 % | -21,10 % | -23,63 % |
Company Profile for GENMAB AS DK 1 Share
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Invested Funds
The following funds have invested in: GENMAB AS DK 1 invested:
Fund | Vol. in million 832,16 | Percentage (%) 1,91 % |
Fund | Vol. in million 1.158,01 | Percentage (%) 1,35 % |
Fund | Vol. in million 110,52 | Percentage (%) 1,35 % |
Fund | Vol. in million 175,99 | Percentage (%) 1,14 % |
Fund | Vol. in million 7.713,76 | Percentage (%) 1,10 % |
Company Data
Name GENMAB AS DK 1
Company Genmab A/S
Website
https://www.genmab.com
Primary Exchange
NASDAQ COPENHAGEN A/S
WKN 565131
ISIN DK0010272202
Asset Class Share
CEO Dr. Jan G.J. van de Winkel Ph.D.
Market Capitalization 11 Mrd.
Country Denmark
Currency EUR
Employees 2,7 T
Address Carl Jacobsens Vej 30, 2500 Copenhagen
IPO Date 2000-10-23
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | GE9.F |
More Shares
Investors who GENMAB AS DK 1 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.